Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

HLA-DMA Protein (AA 27-233) (His tag)

HLA-DMA Spezies: Human Wirt: Escherichia coli (E. coli) Recombinant Greater than 95 % as determined by SDS-PAGE ELISA, WB
Produktnummer ABIN7123830
  • Target Alle HLA-DMA Proteine anzeigen
    HLA-DMA (Major Histocompatibility Complex, Class II, DM alpha (HLA-DMA))
    Protein-Typ
    Recombinant
    Proteineigenschaft
    AA 27-233
    Spezies
    Human
    Quelle
    • 2
    • 1
    Escherichia coli (E. coli)
    Aufreinigungstag / Konjugat
    Dieses HLA-DMA Protein ist gelabelt mit His tag.
    Applikation
    ELISA, Western Blotting (WB)
    Reinheit
    Greater than 95 % as determined by SDS-PAGE
    Sterilität
    0.2 μm filtered
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Centrifuge the vial at 10,000 rpm for 1 minute, reconstitute at 200 μg/mL in sterile distilled water by gentle pipetting 2-3 times, don't vortex
    Buffer
    Lyophilized from a 0.2 μm filtered solution in 10 mM Hepes, 500 mM NaCl with 5 % trehalose, pH 7.4
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    -20°C for 12 months as lyophilized, 2-8°C for 1 month under sterile conditions after reconstitution
    Haltbarkeit
    12 months
  • Target
    HLA-DMA (Major Histocompatibility Complex, Class II, DM alpha (HLA-DMA))
    Andere Bezeichnung
    HLA-DMA (HLA-DMA Produkte)
    Synonyme
    RT1.Ma Protein, RT1.DMa Protein, HLA-DMA Protein, H-2Ma Protein, H2-Ma Protein, D6S222E Protein, DMA Protein, HLADM Protein, RING6 Protein, RT1 class II, locus DMa Protein, SLA-DM alpha chain Protein, major histocompatibility complex, class II, DM alpha Protein, histocompatibility 2, class II, locus DMa Protein, RT1-DMa Protein, SLA-DMA Protein, DLA-DMA Protein, H2-DMa Protein, HLA-DMA Protein
    Molekulargewicht
    22.7 kDa
    UniProt
    Q6ICR9
    Pathways
    Cancer Immune Checkpoints
Sie sind hier: